• Flow cytometric analysis of Hela cells using THAP11 monoclonal antibody (green) and negative control (purple).
  • Immunohistochemistry analysis of paraffin-embedded colon cancer tissues (left) and ovary cancer tissues (right) with DAB staining using THAP11 monoclonal antibody.
  • Immunofluorescence analysis of NTERA-2 cells using THAP11 monoclonal antibody (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
  • Western blot analysis using THAP11 monoclonal antibody against HeLa (1) and NTERA-2 (2) cell lysate.

Anti-THAP11 antibody [3F3] (STJ98419)

SKU:
STJ98419

Current Stock:
Host: Mouse
Applications: WB/IHC/IF/FC/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-THAP domain-containing protein 11 is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence, Flow Cytometry and ELISA research applications.
Clonality: Monoclonal
Clone ID: 3F3
Conjugation: Unconjugated
Isotype: IgG1
Formulation: Liquid in PBS containing 0.03% Sodium Azide, 0.5% BSA, 50% Glycerol.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
IHC 1:200-1:1000
IF 1:200-1:1000
FC 1:200-1:400
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: THAP11
Gene ID: 57215
Uniprot ID: THA11_HUMAN
Specificity: THAP11 Monoclonal Antibody detects endogenous levels of THAP11 protein.
Immunogen: Purified recombinant fragment of human THAP11 expressed in E. Coli.
Protein Name Thap Domain-Containing Protein 11
Cellular Localisation Nucleus
Cytoplasm
May Be Regulated By Shuttling Of The Protein Between The Cytoplasm And Nucleus
Alternative Antibody Names Anti-Thap Domain-Containing Protein 11 antibody
Anti-THAP11 antibody
Anti-HRIHFB2206 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance